Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01860937 · ClinicalTrials.gov registry record · Phase 1
T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
A Phase 1 study of Relapsed B-Cell Acute Lymphoblastic Leukemia, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
- 2
- Study locations
NCT01860937 is a Phase 1 study of Relapsed B-Cell Acute Lymphoblastic Leukemia that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 23 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT01860937, a Phase 1 study of Relapsed B-Cell Acute Lymphoblastic Leukemia, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to test the safety of giving the patient special cells made from their own blood called "Modified T-cells". The goal is to find a safe dose of modified T-cells for patients whose leukemia has returned to the bone marrow.
Conditions Studied
Interventions
- PROCEDURE leukapheresis or collection of PBMCs
- DRUG cyclophosphamide based chemotherapy regimens
- BIOLOGICAL modified T cells
Study Locations (2)
Massachusetts
- Dana-Farber Cancer Institute:Dana- Farber/Children's Hospital - Boston
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2013-05 |
| Est. Completion | 2026-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01860937
The ClinicalTrials.gov registry entry for NCT01860937 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed B-Cell Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 3 interventions - of which leukapheresis or collection of PBMCs is the first listed.
NCT01860937 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT01860937 about?
NCT01860937 is a clinical study titled "T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia". The purpose of this study is to test the safety of giving the patient special cells made from their own blood called "Modified T-cells". The goal is to find a safe dose of modified T-cells for patients whose leukemia has returned to the bone marrow.
What is the current status of trial NCT01860937?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2013-05. Estimated completion is 2026-05.
What conditions does trial NCT01860937 study?
This clinical trial studies the following conditions: Relapsed B-Cell Acute Lymphoblastic Leukemia.
What interventions are being tested in trial NCT01860937?
The interventions under investigation include: leukapheresis or collection of PBMCs (PROCEDURE), cyclophosphamide based chemotherapy regimens (DRUG), modified T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT01860937?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01860937 being conducted?
This trial has 2 study locations across Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed B-Cell Acute Lymphoblastic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.